RxDoctor Payments Data

Michael Lobianco, DO

Family Medicine · Philadelphia, PANPI 1902898174

Payments from drug & device makers

$13,944in general payments, 2019–2025

Across 805 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • GSK$1K
  • Boehringer Ingelheim$870
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$13,86999%
  • Education$761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,944 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$107,784
Medicare patients
298
Services billed
1,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$61,724
JardianceEmpagliflozin56$57,348
MounjaroTirzepatide49$54,843
OzempicSemaglutide39$41,121
JanumetSitagliptin Phos/Metformin Hcl27$32,512
FarxigaDapagliflozin Propanediol24$28,539
XareltoRivaroxaban23$26,571
MyrbetriqMirabegron28$22,180
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$16,427
LinzessLinaclotide18$14,626
NamzaricMemantine Hcl/Donepezil Hcl19$13,314
TrulicityDulaglutide13$12,499
Janumet XrSitagliptin Phos/Metformin Hcl17$12,385
TrintellixVortioxetine Hydrobromide13$10,762
SymbicortBudesonide/Formoterol Fumarate29$9,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$870$72,64682 claims
Lilly USA, LLCMounjaro, Trulicity$1,181$67,34262 claims
PfizerEliquis$683$61,72454 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,557$54,38280 claims
MerckJanumet, Janumet Xr$280$44,89744 claims
Novo NordiskOzempic$1,406$41,12139 claims
AbbVieLinzess, Namzaric$1,815$27,93937 claims
Johnson & JohnsonXarelto$509$26,57123 claims
Astellas Pharma US IncMyrbetriq$547$22,18028 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$437$10,76213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →